Trial Profile
A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Veverimer (Primary)
- Indications Metabolic acidosis; Renal failure
- Focus Registrational; Therapeutic Use
- Acronyms VALOR-CKD
- Sponsors Tricida
- 01 Mar 2024 Results Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis, published in the Journal of the American Society of Nephrology
- 08 Feb 2024 This trial has been completed in Portugal (Date of the global end of the trial : 27-Sep-2022),
- 12 Jan 2023 This trial has been completed in Poland (Date of the global end of the trial : 27-Sep-2022), according to European Clinical Trials Database record.